Evidence map›Paper›PMID 40528347›Full record

ArticleHGG advances2025

Identification of technically challenging variants: Whole-genome sequencing improves diagnostic yield in patients with high clinical suspicion of rare diseases.

Hau-Yee Ng, Wei Ma, Wai-Kei J Lam, Chak-Sing Lau, Ho-Ming Luk, Lisa W C Au, Shirley S W Cheng, Josephine S C Chong, Stephanie Ho, Becky M Ma and 4 more

Abstract read
In one paragraph

Article in HGG advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hau-Yee NgHong Kong Genome Institute, Hong Kong, China.
Wei MaHong Kong Genome Institute, Hong Kong, China.
Wai-Kei J LamDepartment of Chemical Pathology, the Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China; Li Ka Shing Institute of Health Sciences, the Chinese University of Hong Kong, Hong Kong, China.
Chak-Sing LauDepartment of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong, China.
Ho-Ming LukDepartment of Clinical Genetics, Hong Kong Children's Hospital, Hong Kong, China.
Lisa W C AuDepartment of Medicine and Therapeutics, the Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.
Shirley S W ChengDepartment of Clinical Genetics, Hong Kong Children's Hospital, Hong Kong, China.
Josephine S C ChongDepartment of Paediatrics, the Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.
Stephanie HoDepartment of Clinical Genetics, Hong Kong Children's Hospital, Hong Kong, China.
Becky M MaDivision of Nephrology, Department of Medicine, Queen Mary Hospital, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong, China.
Shirley Y Y PangDivision of Neurology, Department of Medicine, Queen Mary Hospital, School of Clinical Medicine, the University of Hong Kong, Hong Kong, China.
Hong Kong Genome Project
Annie T W ChuHong Kong Genome Institute, Hong Kong, China.
Brian H Y ChungHong Kong Genome Institute, Hong Kong, China; Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong, China. Electronic address: bhychung@genomics.org.hk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The total burden of rare diseases is significant worldwide, with over 300 million people being affected. Many rare diseases have both well-defined clinical phenotypes and established genetic causes. However, a remarkable proportion of patients with high clinical suspicion of a rare disease remain genetically undiagnosed and stuck in the diagnostic odyssey after having a cascade of conventional genetic tests. One of the major factors contributing to this is that many types of variants are technically intractable to whole-exome sequencing (WES). In this study, the added diagnostic power of whole-genome sequencing (WGS) for patients with clinically suspected rare diseases was assessed by detecting technically challenging variants. 3,169 patients from the Hong Kong Genome Project (HKGP) were reviewed, identifying 322 individuals having high clinical suspicion of a rare disorder with well-established genetic etiology. Notably, 180 patients have performed at least one previous genetic test. Through PCR-free short-read WGS and a comprehensive in-house analytic pipeline, causative variants were found in 138 patients (138 of 322, 42.9%), 30 of which (30 of 138, 21.7%) are attributed to technically challenging variants. These included 6 variants in low-coverage regions with PCR bias, 2 deep intronic variants, 2 repeat expansions, 19 structural variants, and 2 variants in genes with a homologous pseudogene. The study demonstrated the indispensable diagnostic power of WGS in detecting technically challenging variants and the capability to serve as an all-in-one test for patients with high clinical suspicion of rare diseases.

Indexed as

Genetic VariationRare DiseasesWhole Genome SequencingAdultChildExome SequencingFemaleGenetic TestingHumansMalechallenging variantsnon-coding variantspseudogenesrare diseasesrepeat expansionsstructural variantswhole genome sequencing

Identifiers

PMID40528347
PMCPMC12269974

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.